HS patient satisfaction after starting Cosentyx in Saudi clinics
Part of Infections, Skin clinical trials.
This study measures how satisfied people with moderate to severe hidradenitis suppurativa (HS) feel with their treatment after starting Cosentyx. It is for adults in Saudi Arabia who have not taken Cosentyx before and are starting it as part of their routine care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You have been diagnosed with active moderate to severe hidradenitis suppurativa (HS).
- You have never taken Cosentyx (secukinumab) before, and your first dose will be within a month of signing the consent form.
- You are willing to take Cosentyx as prescribed by your doctor (can also use antibiotics or have had surgery).
- You agree to fill out questionnaires about your HS and treatment satisfaction.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a drug called secukinumab (a self-injected biologic) is safe and effective for adults with moderate-to-severe hidradenitis suppurativa (HS) in China. It may help reduce the number of painful HS lesions.
This study tests a drug called secukinumab (a type of biologic that targets inflammation) for people with moderate to severe hidradenitis suppurativa (HS). It may be an option if you have tried other treatments and they didn't work well.
This study looks at certain immune cells (called MAIT cells) in the skin of people with hidradenitis suppurativa, a painful skin condition. It will compare samples from people before they start a new biologic treatment, and may help doctors understand how these treatments work.
This study tests whether applying secukinumab as a topical cream or as a subcutaneous injection is more effective and safer for treating hidradenitis suppurativa (a skin condition causing painful lumps). It aims to find a better way to manage symptoms in people whose condition has not improved with standard treatments.
This trial tests whether combining the drug secukinumab with surgery can help people with moderate to severe hidradenitis suppurativa (HS). It looks at how well this combination works and if it is safe over a year.
This program gives access to a medicine called secukinumab (brand name Cosentyx) for people with serious conditions who have run out of other treatment options and cannot join a clinical trial. It is a special access program for when standard care is not enough.
Hear when a new Hidradenitis Suppurativa (HS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.